Julie Ahn

Ms. Julie Ahn

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
JAJulie Ahn
Julie Ahn
MAMohammad Abu-Rub
Mohammad Abu-Rub
Robert H. MillerRobert H. Miller
Robert H. Miller
In recent years, the role of B cells in neurological disorders has substantially expanded our perspectives on mechanisms of neuroinflammation. The success of B cell-depleting therapies in patients with CNS diseases such as neuromyelitis optica and multiple sclerosis has highlighted the importance of neuroimmune crosstalk in inflammatory processes. While B cells are essential for the adaptive immune system and antibody production, they are also major contributors of pro- and anti-inflammatory cytokine responses in a number of inflammatory diseases. B cells can contribute to neurological diseases through peripheral immune mechanisms, including production of cytokines and antibodies, or through CNS mechanisms following compartmentalization. Emerging evidence suggests that aberrant pro- or anti-inflammatory B cell populations contribute to neurological processes, including glial activation, which has been implicated in the pathogenesis of several neurodegenerative diseases. In this review, we summarize recent findings on B cell involvement in neuroinflammatory diseases and discuss evidence to support pathogenic immunomodulatory functions of B cells in neurological disorders, highlighting the importance of B cell-directed therapies.

9 April 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
DGDaria A. Gaykalova
Daria A. Gaykalova
JMJudith B. Manola
Judith B. Manola
HOHiroyuki Ozawa
Hiroyuki Ozawa
VZVeronika Zizkova
Veronika Zizkova
KMKathryn Morton
Kathryn Morton
JCJoseph A. Califano
Joseph A. Califano
Using high‐throughput analyses and the TRANSFAC database, we characterized TF signatures of head and neck squamous cell carcinoma (HNSCC) subgroups by inferential analysis of target gene expression, correcting for the effects of DNA methylation and copy number. Using this discovery pipeline, we determined that human papillomavirus‐related (HPV+) and HPV− HNSCC differed significantly based on the activity levels of key TFs including AP1, STATs, NF‐κB and p53. Immunohistochemical analysis confirmed that HPV− HNSCC is characterized by co‐activated STAT3 and NF‐κB pathways and functional studies demonstrate that this phenotype can be effectively targeted with combined anti‐NF‐κB and anti‐STAT therapies. These discoveries correlate strongly with previous findings connecting STATs, NF‐κB and AP1 in HNSCC. We identified five top‐scoring pair biomarkers from STATs, NF‐κB and AP1 pathways that distinguish HPV+ from HPV− HNSCC based on TF activity and validated these biomarkers on TCGA and on independent validation cohorts. We conclude that a novel approach to TF pathway analysis can provide insight into therapeutic targeting of patient subgroup for heterogeneous disease such as HNSCC.

13 March 2015 in Cancer
Verified
Journal Article
Open access
PDF file
MHMasamichi Hayashi
Masamichi Hayashi
GWGaosong Wu
Gaosong Wu
JRJong‐Lyel Roh
Jong‐Lyel Roh
XCXiaofei Chang
Xiaofei Chang
XLXiufeng Li
Xiufeng Li
WKWayne M. Koch
Wayne M. Koch
BACKGROUND: Securing negative surgical margins is a critical goal for head and neck surgery. Local recurrence develops even in some patients who have histologically negative surgical margins. Minimal residual tumor cells may lead to locoregional recurrence despite clear histologic margins reported at the time of resection of head and neck squamous cell carcinoma (HNSCC). To identify subclinical residual disease, the authors analyzed deep margin imprint samples collected on 1‐layer nitrocellulose sheets.METHODS: Bisulfite‐treated DNA samples from 73 eligible patients were amplified by quantitative methylation‐specific polymerase chain reaction (QMSP) targeting 6 genes (deleted in colorectal cancer [DCC], endothelin receptor type B [EDNRB], homeobox protein A9 [HOXA9], kinesin family member 1A [KIF1A], nidogen‐2 [NID2], and N‐methyl D‐aspartate receptor subtype 2B [NR2B]). QMSP values were dichotomized as positive or negative. Associations between the QMSP status of deep margin samples and clinical outcomes were evaluated.RESULTS: Two‐gene methylation combinations among the genes DCC, EDNRB, and HOXA9 were associated with decreased locoregional recurrence‐free survival, recurrence‐free survival, and overall survival. The methylated gene combination of EDNRB and HOXA9 in margin imprints was the most powerful predictor of poor locoregional recurrence‐free survival (hazard ratio [HR], 3.31; 95% confidence interval [CI], 1.30‐8.46; P = .012) independent of standard histologic factors. In addition, methylation of both EDNRB and HOXA9 indicated a trend toward reduced recurrence‐free survival (HR, 2.74; 95% CI, 0.90‐8.33; P = .075) and reduced OS (HR, 5.78; 95% CI, 0.75‐44.7; P = .093) in multivariable analysis.CONCLUSIONS: A panel of gene methylation targets in deep surgical margin imprints provides a potential predictive marker of postoperative locoregional recurrence. Intraoperative use of molecular margin imprint analysis may assist surgeons in obtaining rigorously negative surgical margins and improve the outcome of head and neck surgery. Cancer 2015;121:1957–1965. © 2015 American Cancer Society.

6 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DGDaria A Gaykalova
Daria A Gaykalova
RVRajita Vatapalli
Rajita Vatapalli
YWYingying Wei
Yingying Wei
HTHua-Ling Tsai
Hua-Ling Tsai
HWHao Wang
Hao Wang
JCJoseph A. Califano
Joseph A. Califano
Head and Neck Squamous Cell Carcinoma (HNSCC) is the fifth most common cancer, annually affecting over half a million people worldwide. Presently, there are no accepted biomarkers for clinical detection and surveillance of HNSCC. In this work, a comprehensive genome-wide analysis of epigenetic alterations in primary HNSCC tumors was employed in conjunction with cancer-specific outlier statistics to define novel biomarker genes which are differentially methylated in HNSCC. The 37 identified biomarker candidates were top-scoring outlier genes with prominent differential methylation in tumors, but with no signal in normal tissues. These putative candidates were validated in independent HNSCC cohorts from our institution and TCGA (The Cancer Genome Atlas). Using the top candidates, ZNF14, ZNF160, and ZNF420, an assay was developed for detection of HNSCC cancer in primary tissue and saliva samples with 100% specificity when compared to normal control samples. Given the high detection specificity, the analysis of ZNF DNA methylation in combination with other DNA methylation biomarkers may be useful in the clinical setting for HNSCC detection and surveillance, particularly in high-risk patients. Several additional candidates identified through this work can be further investigated toward future development of a multi-gene panel of biomarkers for the surveillance and detection of HNSCC.

22 September 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JAJulie Ahn
Julie Ahn
JBJustin A. Bishop
Justin A. Bishop
RRRichard B. S. Roden
Richard B. S. Roden
CAClint T. Allen
Clint T. Allen
SBSimon R. A. Best
Simon R. A. Best

27 March 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MHMasamichi Hayashi
Masamichi Hayashi
RGRafael Guerrero-Preston
Rafael Guerrero-Preston
JOJun Okamura
Jun Okamura
CMChristina Michailidi
Christina Michailidi
ZKZubair Kahn
Zubair Kahn
WKWayne Koch
Wayne Koch